Search clinical trials for: Rivaroxaban (BAY59-7939, Xarelto)

Total 246 results

Janssen Research & Development, LLC
Bayer

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

End-Stage Renal Disease

United States
Bayer

Completed

Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany

Venous Thromboembolism

Germany
Bayer
Janssen, LP

Completed

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid (XATOA)

Atherosclerosis

Germany, Argentina, Brazil, Canada, Denmark, Israel, Korea, Republic of, Lebanon, Luxembourg, Mexico, Norway, Russian Federation, Slovenia, Sweden, Switzerland, Thailand, United Arab Emirates, United Kingdom
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Terminated

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (NAVIGATE ESUS)

Stroke

Denmark, France, Spain, China, United States, Switzerland, Germany, Greece, Korea, Republic of, Portugal, Japan, Israel, Canada, Australia, Turkey, Russian Federation, Sweden, Austria, Czechia, Poland, United Kingdom, Belgium, Brazil, Hungar... and more
Bayer
Janssen, LP

Completed

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice (SiERRA UK)

Atrial Fibrillation

United Kingdom
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)

Treatment of Venous Thromboembolism in Cancer Patients

Sweden
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Completed

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Prevention & Control

Belgium, Finland, France, China, United States, Colombia, Ireland, Philippines, Japan, Hungary, Canada, Germany, Australia, Chile, Czechia, Korea, Republic of, Malaysia, Brazil, Denmark, Israel, Russian Federation, South Africa, Ecu... and more
Jilin University

Recruiting

Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction (ACTonLVT)

ST-segment Elevation Myocardial Infarction (STEMI) | Left Ventricular Thrombus

China
Ottawa Heart Institute Research Corporation

Recruiting

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Radial Artery Occlusion

Canada
Bayer
Janssen Research & Development, LLC

Completed

Xarelto Regulatory Post-Marketing Surveillance

Venous Thromboembolism

Korea, Republic of
University of Padova

Terminated

Rivaroxaban in Thrombotic Antiphospholipid Syndrome (TRAPS)

Antiphospholipid Syndrome

Italy
Sherief Abd-Elsalam

Unknown

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Portal Vein Thrombosis

Egypt
The Affiliated Hospital of Qingdao University

Completed

Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers

Healthy Subjects

China
Hospital Alemão Oswaldo Cruz
Bayer; Hospital Israelita Albert Einstein; Hospital Moinhos de Vento; Brazilian... and other collaborators

Terminated

COVID-19 Antithrombotic Rivaroxaban Evaluation (CARE)

COVID-19

Brazil
State University of New York - Upstate Medical...

Terminated

Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery

Gastric Bypass Status

United States
University Hospital, Grenoble

Completed

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics (REVNEWANTICO)

Venous Thromboembolism

France
University of Alberta

Completed

Rivaroxaban in Type 2 Myocardial Infarctions (R2MI)

Type II Myocardial Infarction

Canada
Chiayi Christian Hospital

Recruiting

Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty

Arthroplasty | Venous Thromboembolism

Taiwan
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effect of Rivaroxaban in Sickle Cell Disease

Sickle Cell Anemia | Sickle Cell-Beta0-Thalassemia

United States
Ottawa Hospital Research Institute
Canadian Institutes of Health Research (CIHR); Canadian Venous Thromboembolism... and other collaborators

Not yet recruiting

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy (PREVENT-GU)

Venous Thromboembolism | Urologic Cancer
University of Michigan

Withdrawn

Evaluation of Wound Drainage After Knee or Hip Arthroplasty

Complications; Arthroplasty

United States
Second Xiangya Hospital of Central South University

Completed

Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome (H-REPLACE)

Myocardial Infarction | Myocardial Ischemia | Acute Coronary Syndrome | Unstable Angina

China
Hospital Geral Roberto Santos

Terminated

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis (RIWA)

Stroke | Valve Heart Disease | Anticoagulants and Bleeding Disorders | Prostheses and Implants

Brazil
The George Institute
Bayer; King Abdullah International Medical Research Center; George Clinical Pty... and other collaborators

Recruiting

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK)

Cardiovascular Disease | Chronic Kidney Diseases | Dialysis-dependent Kidney Failure

Taiwan, Australia, Malaysia, Tunisia, Singapore, Canada, France, India, Saudi Arabia
Insel Gruppe AG, University Hospital Bern

Completed

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial (ELAN)

Ischaemic Stroke

Belgium, Ireland, Israel, Germany, India, United Kingdom, Austria, Switzerland, Finland, Norway, Italy, Portugal, Slovakia, Japan, Greece
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists (ANTENNA)

Non-Valvular Atrial Fibrillation

United Kingdom
Seoul National University Hospital
Seoul National University Bundang Hospital; Daegu Catholic University Medical... and other collaborators

Unknown

Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study (PRAIS)

Ileofemoral Deep Vein Thrombosis

Korea, Republic of
Kevin H.M. Kuo, MD, MSc, FRCPC

Recruiting

THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS) (THIS)

Sickle Cell Disease | Venous Thromboembolism | Central Venous Catheter Thrombosis

Canada
Ottawa Hospital Research Institute
University of Alberta; Hamilton Health Sciences Corporation; Queen Elizabeth...

Completed

Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines (TRIM-Line)

Cancer | Central Venous Catheter Thrombosis | Upper Extremity Deep Vein Thrombosis

Canada
Insel Gruppe AG, University Hospital Bern
Bayer; Janssen Pharmaceuticals

Completed

Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery (BARIVA)

Bariatric Surgery

Switzerland
The Young Investigator Group of Cardiovascular...

Completed

Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi (No-LVT)

Left Ventricular Thrombosis | Anticoagulants; Increased

Egypt
Xijing Hospital

Unknown

Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events (TRACE)

Ischemic Stroke | TIA

China
Bayer
Janssen, LP

Completed

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Atrial Fibrillation

Sweden
Bayer
Janssen Research & Development, LLC

Terminated

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes (GALILEO)

Transcatheter Aortic Valve Replacement

Belgium, France, Germany, Spain, United States, Switzerland, Canada, Austria, United Kingdom, Korea, Republic of, Denmark, Italy, Netherlands, Poland, Czechia, Sweden, Norway
Hanoi Medical University
Bach Mai Hospital

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching

Thrombosis | Deep Vein Thrombosis | Surgery--Complications

Vietnam
Bayer

Active, not recruiting

Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)

Coronary Artery Disease (CAD) | Prevention of Atherothrombotic Events | Symptomatic Peripheral Artery Disease (Symptomatic PAD)

India
Susan Smyth
Janssen Scientific Affairs, LLC

Terminated

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis (XENITH)

Venous Thrombosis | Pulmonary Embolism
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
China-Japan Friendship Hospital

Not yet recruiting

Effectiveness and Safety of Rivaroxaban Used in Extended Anticoagulation for Pulmonary Embolism Patients

Pulmonary Embolism
Assistance Publique - Hôpitaux de Paris

Completed

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. (RIPORT)

Deep Vein Thrombosis | Chronic Portal Vein Thrombosis

France
Fundació Institut de Recerca de l'Hospital de la...
Daiichi Sankyo

Recruiting

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD) (MACACOD)

Atrial Fibrillation | Recurrent Venous Thromboembolism

Spain
University of Florida
Janssen Scientific Affairs, LLC

Completed

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

Coronary Artery Disease | Peripheral Arterial Disease | Atrial Fibrillation

United States
RWTH Aachen University
Bayer

Completed

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

Atrial Fibrillation or Pulmonary Embolism | Need of Long Term Oral Anticoagulation Therapy (OAT) | Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location

Germany
Ostfold Hospital Trust

Completed

Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study (Ri-Schedule)

Deep Venous Thrombosis

Norway
Azienda Ospedaliero, Universitaria Ospedali Riuniti

Recruiting

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

Intracardiac Thrombus

Italy
Genuine Research Center, Egypt
Horus for Pharmaceutical Industries, Egypt

Completed

Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)

Healthy

Egypt
Asan Medical Center
Bayer

Recruiting

Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation (SPIRIT)

Coronary Artery Disease | Peripheral Arterial Disease | Carotid Stenosis | Atherosclerosis of Artery

Korea, Republic of
Radboud University Medical Center
Amgen

Completed

Rivaroxaban Sotorasib Interaction Study (ROSIE)

Drug Drug Interaction Study

Netherlands
Seoul National University Hospital
Korean Society of Hematology Thrombosis Working Party

Completed

Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Recurrence | Bleeding | Cancer-associated Thrombosis | Rivaroxaban

Korea, Republic of

Search clinical trials for: Rivaroxaban (BAY59-7939, Xarelto)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations